Mogy Joel R Investment Counsel Inc. trimmed its position in Danaher Co. (NYSE:DHR – Get Rating) by 90.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100 shares of the conglomerate’s stock after selling 900 shares during the quarter. Mogy Joel R Investment Counsel Inc.’s holdings in Danaher were worth $33,000 as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in DHR. D Orazio & Associates Inc. bought a new position in Danaher during the third quarter worth about $27,000. Maryland Capital Advisors Inc. bought a new position in Danaher during the fourth quarter worth about $28,000. Dixon Hughes Goodman Wealth Advisors LLC bought a new position in Danaher during the fourth quarter worth about $29,000. Lee Financial Co bought a new position in Danaher during the fourth quarter worth about $30,000. Finally, Evolution Advisers Inc. bought a new position in Danaher during the fourth quarter worth about $32,000. Hedge funds and other institutional investors own 78.42% of the company’s stock.
Shares of NYSE:DHR traded up $9.64 during trading on Friday, hitting $249.19. 3,163,706 shares of the company were exchanged, compared to its average volume of 2,979,738. The stock has a market cap of $181.18 billion, a price-to-earnings ratio of 28.84, a P/E/G ratio of 2.63 and a beta of 0.84. Danaher Co. has a fifty-two week low of $233.71 and a fifty-two week high of $333.96. The firm has a fifty day moving average price of $272.46 and a two-hundred day moving average price of $289.54. The company has a current ratio of 1.68, a quick ratio of 1.27 and a debt-to-equity ratio of 0.51.
The business also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Friday, June 24th will be given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 0.40%. The ex-dividend date is Thursday, June 23rd. Danaher’s dividend payout ratio (DPR) is 11.57%.
A number of equities analysts have issued reports on the company. Royal Bank of Canada reduced their target price on Danaher from $311.00 to $299.00 and set a “sector perform” rating on the stock in a report on Friday, April 22nd. UBS Group cut their price objective on Danaher from $365.00 to $340.00 in a report on Sunday, April 24th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Friday, April 22nd. Zacks Investment Research cut Danaher from a “buy” rating to a “hold” rating and set a $278.00 price objective on the stock. in a report on Monday, April 25th. Finally, Barclays cut their price objective on Danaher from $355.00 to $325.00 and set an “overweight” rating on the stock in a report on Thursday, January 27th. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, Danaher has a consensus rating of “Buy” and an average target price of $331.14.
In related news, EVP Joakim Weidemanis sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, April 25th. The stock was sold at an average price of $255.74, for a total transaction of $1,662,310.00. Following the transaction, the executive vice president now directly owns 86,398 shares of the company’s stock, valued at approximately $22,095,424.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.20% of the stock is currently owned by insiders.
About Danaher (Get Rating)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.
- Get a free copy of the StockNews.com research report on Danaher (DHR)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.